Baricitinib : Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy?
| Errataetall: |
CommentOn: Clin Infect Dis. 2021 Apr 8;72(7):1247-1250. - PMID 32597466 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:73 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 73(2021), 11 vom: 06. Dez., Seite e3978-e3979 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jorgensen, Sarah C J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Azetidines |
|---|
| Anmerkungen: |
Date Completed 13.12.2021 Date Revised 07.12.2022 published: Print CommentOn: Clin Infect Dis. 2021 Apr 8;72(7):1247-1250. - PMID 32597466 Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciaa1208 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313718695 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313718695 | ||
| 003 | DE-627 | ||
| 005 | 20231225151156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciaa1208 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1045.xml |
| 035 | |a (DE-627)NLM313718695 | ||
| 035 | |a (NLM)32797237 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jorgensen, Sarah C J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Baricitinib |b Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Clin Infect Dis. 2021 Apr 8;72(7):1247-1250. - PMID 32597466 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a Azetidines |2 NLM | |
| 650 | 7 | |a Purines |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a baricitinib |2 NLM | |
| 650 | 7 | |a ISP4442I3Y |2 NLM | |
| 700 | 1 | |a Burry, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Tse, Christopher L Y |e verfasserin |4 aut | |
| 700 | 1 | |a Dresser, Linda D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 73(2021), 11 vom: 06. Dez., Seite e3978-e3979 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:73 |g year:2021 |g number:11 |g day:06 |g month:12 |g pages:e3978-e3979 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciaa1208 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 73 |j 2021 |e 11 |b 06 |c 12 |h e3978-e3979 | ||